These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 14656478)

  • 1. AMH signaling: from receptor to target gene.
    Visser JA
    Mol Cell Endocrinol; 2003 Dec; 211(1-2):65-73. PubMed ID: 14656478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic studies of the AMH/MIS signaling pathway for Müllerian duct regression.
    Jamin SP; Arango NA; Mishina Y; Hanks MC; Behringer RR
    Mol Cell Endocrinol; 2003 Dec; 211(1-2):15-9. PubMed ID: 14656471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Components of the anti-Müllerian hormone signaling pathway in gonads.
    di Clemente N; Josso N; Gouédard L; Belville C
    Mol Cell Endocrinol; 2003 Dec; 211(1-2):9-14. PubMed ID: 14656470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling.
    Visser JA; Olaso R; Verhoef-Post M; Kramer P; Themmen AP; Ingraham HA
    Mol Endocrinol; 2001 Jun; 15(6):936-45. PubMed ID: 11376112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
    Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK
    Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor.
    Gouédard L; Chen YG; Thevenet L; Racine C; Borie S; Lamarre I; Josso N; Massague J; di Clemente N
    J Biol Chem; 2000 Sep; 275(36):27973-8. PubMed ID: 10854429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
    Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
    Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
    Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK
    Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Müllerian hormone and its receptors.
    Josso N; di Clemente N; Gouédard L
    Mol Cell Endocrinol; 2001 Jun; 179(1-2):25-32. PubMed ID: 11420127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AMH and AMH receptor defects in persistent Müllerian duct syndrome.
    Josso N; Belville C; di Clemente N; Picard JY
    Hum Reprod Update; 2005; 11(4):351-6. PubMed ID: 15878900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Requirement of Bmpr1a for Müllerian duct regression during male sexual development.
    Jamin SP; Arango NA; Mishina Y; Hanks MC; Behringer RR
    Nat Genet; 2002 Nov; 32(3):408-10. PubMed ID: 12368913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autocrine and paracrine Müllerian inhibiting substance hormone signaling in reproduction.
    Ingraham HA; Hirokawa Y; Roberts LM; Mellon SH; McGee E; Nachtigal MW; Visser JA
    Recent Prog Horm Res; 2000; 55():53-67; discussion 67-8. PubMed ID: 11036933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Müllerian hormone, beta-catenin and Müllerian duct regression.
    Xavier F; Allard S
    Mol Cell Endocrinol; 2003 Dec; 211(1-2):115-21. PubMed ID: 14656484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of a matrix metalloproteinase in MIS-induced cell death during urogenital development.
    Roberts LM; Visser JA; Ingraham HA
    Development; 2002 Mar; 129(6):1487-96. PubMed ID: 11880357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Müllerian hormone receptor defect.
    di Clemente N; Belville C
    Best Pract Res Clin Endocrinol Metab; 2006 Dec; 20(4):599-610. PubMed ID: 17161334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Catenin is essential for Müllerian duct regression during male sexual differentiation.
    Kobayashi A; Stewart CA; Wang Y; Fujioka K; Thomas NC; Jamin SP; Behringer RR
    Development; 2011 May; 138(10):1967-75. PubMed ID: 21490063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Welcome to the family: the anti-müllerian hormone receptor.
    Grootegoed JA; Baarends WM; Themmen AP
    Mol Cell Endocrinol; 1994 Apr; 100(1-2):29-34. PubMed ID: 8056154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional redundancy of TGF-beta family type I receptors and receptor-Smads in mediating anti-Mullerian hormone-induced Mullerian duct regression in the mouse.
    Orvis GD; Jamin SP; Kwan KM; Mishina Y; Kaartinen VM; Huang S; Roberts AB; Umans L; Huylebroeck D; Zwijsen A; Wang D; Martin JF; Behringer RR
    Biol Reprod; 2008 Jun; 78(6):994-1001. PubMed ID: 18322278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of ovarian function: the role of anti-Müllerian hormone.
    Durlinger AL; Visser JA; Themmen AP
    Reproduction; 2002 Nov; 124(5):601-9. PubMed ID: 12416998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of hormone-mediated Müllerian duct regression: involvement of beta-catenin.
    Allard S; Adin P; Gouédard L; di Clemente N; Josso N; Orgebin-Crist MC; Picard JY; Xavier F
    Development; 2000 Aug; 127(15):3349-60. PubMed ID: 10887090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.